Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort
Patients registered in the Late period have less severe psoriasis, shorter disease duration and fewer comorbidities than those enrolled in the Early period. The most frequent biologics at enrolment were adalimumab and ustekinumab; however, this has changed with the introduction of new and more effective biologics. BADBIR is a rich data source providing information on the management of psoriasis.
Authors
- Shehnaz Ahmed (ORCID: https://orcid.org/0000-0003-0744-4985)
- Tess McPherson (ORCID: https://orcid.org/0000-0001-9215-0302)
- Alexa R. Shipman (ORCID: https://orcid.org/0000-0001-5257-4418)
- Philip Hampton (ORCID: https://orcid.org/0000-0001-6797-2697)
- Ian Evans (ORCID: https://orcid.org/0000-0002-0468-8274)
- Simon Morrison
- Zenas Z N Yiu (ORCID: https://orcid.org/0000-0002-1831-074X)
- Girish Kumar Gupta (ORCID: https://orcid.org/0000-0002-6981-4024)
- Olivia Hughes (ORCID: https://orcid.org/0000-0001-9587-9430)
- Philip Laws (ORCID: https://orcid.org/0000-0002-4628-0699)
- Oras Alabas (ORCID: https://orcid.org/0000-0003-2002-0781)
- Nick J. Reynolds (ORCID: https://orcid.org/0000-0002-6484-825X)
- Mark Lunt (ORCID: https://orcid.org/0000-0002-2391-5575)
- Christina Ye
- Teena Mackenzie
- Elise Kleyn
- Anthony D. Ormerod (ORCID: https://orcid.org/0000-0003-4075-6374)
- Shernaz Walton (ORCID: https://orcid.org/0009-0009-1018-1320)
- Ruth Murphy (ORCID: https://orcid.org/0000-0003-2159-5958)
- Juliet N. Barker (ORCID: https://orcid.org/0000-0002-9030-183X)
- Anthony Bewley (ORCID: https://orcid.org/0000-0003-1195-0290)
- Brian Kirby (ORCID: https://orcid.org/0000-0001-7596-892X)
- Christopher E.M. Griffiths (ORCID: https://orcid.org/0000-0001-5371-4427)
- Vera Zietemann (ORCID: https://orcid.org/0000-0002-3382-5506)
- Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
- Catherine Smith (ORCID: https://orcid.org/0000-0001-9918-1144)
- Richard Weller (ORCID: https://orcid.org/0000-0003-2550-9586)
- Christopher Griffiths
- Richard Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
- Kathleen McElhone
Institutions
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Barts Health NHS Trust (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- Manchester Academic Health Science Centre (GB)
- Royal Victoria Infirmary (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- University of Manchester (GB)
- Manchester University NHS Foundation Trust (GB)
- NIHR Newcastle Biomedical Research Centre (GB)
- King's College Hospital (GB)
- NIHR Manchester Biomedical Research Centre (GB)
- University of Newcastle Australia (AU)
- Newcastle University (GB)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1093/ced/llaf224
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- National Institute for Health and Care Research
- British Association of Dermatologists
- LEO Pharma
- Samsung
- UCB Pharma